UnknownEarly Phase 1

Dual SSTR2 and Integrin αvβ3 Targeting PET/CT Imaging

China100 participantsStarted 2016-06-01

Plain-language summary

This is an open-label positron emission tomography/computed tomography (PET/CT) study to investigate the diagnostic performance and evaluate the efficacy of 68Ga-NOTA-3PTATE-RGD in lung cancer patients and neuroendocrine neoplam patients. A single dose of 111-185 Mega-Becquerel (MBq) 68Ga-NOTA-3P-TATE-RGD will be injected intravenously. Visual and semiquantitative method will be used to assess the PET/CT images.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Neoplasm identified by X-ray, ultrasound or MRI as lung cancer or neuroendocrine tumors * To provide basic information and sign the written informed consent. Exclusion Criteria: * Consisted of conditions of mental illness; * Severe liver or kidney disease with serum creatinine \> 3.0 mg/dl (270 μΜ) or any hepatic enzyme level 5 times or more than normal upper limit; * Severe allergy or hypersensitivity to IV radiographic contrast * Claustrophobia to accept the PET/CT scanning * Pregnancy or breast feeding

What they're measuring

Standardized uptake value of 68Ga-NOTA-3PTATE-RGD in lung cancer and Neuroendocrine Neoplasm

Timeframe: 1 year

Trial details

NCT IDNCT02817945

SponsorPeking Union Medical College Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2020-12-01

Contact for this trial

Zhaohui Zhu, MD

+8613611093752 13611093752@163.com

View on ClinicalTrials.gov More Lung Cancer trials